Rational clinical application of quantitative assessments of hepatitis C virus (HCV) RNA depends on an understanding of factors affecting the assay and its intrinsic variability. The effects of three types of blood collection tubes, two storage temperatures, five processing times, and two laboratories on a commercially available quantitative reverse transcriptase PCR assay (AMPLICOR HCV MONITOR) were evaluated. HCV RNA concentrations were assessed in 356 specimens representing 178 aliquots from nine patients. In a multivariate generalized linear model, HCV RNA concentrations decreased when centrifugation was delayed more than 6 h (P ‫؍‬ 0.005) and were marginally different between laboratories (P ‫؍‬ 0.06), but precentrifugation storage temperature (P ‫؍‬ 1.00) and anticoagulation (P ‫؍‬ 0.22) had no effect. After adjusting for other factors, the HCV concentration of 95% of a subject's samples were within 0.44 log. Specimens procured for reverse transcriptase PCR-based quantitative HCV testing should be centrifuged within 6 h of collection. Serial assessments should ideally be performed in the same laboratory, and changes in HCV RNA concentration of less than 0.44 log may not be biologically important.
The hepatitis C virus (HCV), a positively stranded RNA virus similar to pestiviruses, is the principal cause of non-A, non-B hepatitis (2, 3, 5) . At least 80 percent of acute HCV infections persist and may lead to cirrhosis (19, 20) , liver failure, or hepatocellular carcinoma (11) . Extrahepatic manifestations of HCV infection include essential mixed cryoglobulinemia (1, 16) and membranous glomerulonephritis (10) . The only U.S. Food and Drug Administration-approved therapy for chronic HCV, interferon alfa, produces a complete response in less than 30% of individuals, and consequently, chronic HCV infection is a leading indication for orthotopic liver transplantation in the United States (18) .
Antibodies to HCV (anti-HCV) can be detected in the sera of most patients with chronic HCV infection (2, 3, 14) . However, limitations of HCV antibody testing include a 2-to 6-month window of seronegativity after acute infection, occasional falsely reactive antibody, and rare antibody-negative infections (2) (3) (4) 12) . Thus, direct techniques like the reverse transcriptase PCR (RT-PCR) that assess HCV RNA have been developed and have been used to detect early and ongoing HCV infection. The concentration of HCV RNA in serum or plasma can also be evaluated and correlates with the response to therapy and the stage of HCV infection (7) (8) (9) 13) .
The level of HCV RNA can be measured by two commercially available tests, the branched DNA (bDNA) assay of Chiron Corporation (Emeryville, Calif.) and the AMPLICOR HCV quantitative RT-PCR assay of Roche Diagnostic Systems (Branchburg, N.J.). However, there are few data to guide clinicians in the application of quantitative results. Therefore, we systematically evaluated the precision of a quantitative RT-PCR assay and the effects of various procurement conditions on its performance.
MATERIALS AND METHODS

Patients.
From the Outpatient Liver Disease Clinic at the Johns Hopkins Hospital, 10 anti-HCV-positive patients were enrolled in a prospective study of HCV RNA levels. Each patient donated blood in 20 5-ml blood tubes, including 10 containing EDTA, 5 with acid, citrate, and dextrose (ACD), and 5 without anticoagulant (serum). Half of the tubes containing EDTA were placed at 4ЊC, while the remaining 15 tubes containing EDTA, serum, and ACD remained at room temperature. At five intervals after phlebotomy (0, 2, 6, 24, and 48 h), a tube containing EDTA and stored at 4ЊC and one each of the other tube types were centrifuged. Aliquots of plasma or serum were removed and were stored at Ϫ70ЊC. The protocol was approved by the Institutional Review Board of the Johns Hopkins School of Medicine.
Laboratories. Quantitative HCV RNA testing was done under blinded code in two laboratories: (i) laboratory A, the Viral Hepatitis Laboratory, Johns Hopkins University, Baltimore, Md., and (ii) laboratory B, Roche Molecular Systems, Branchburg, N.J.
Quantitative RNA testing. The presence of HCV RNA in a serum specimen from each participant was assessed by guanidine-phenol-chloroform extraction and nested RT-PCR as described previously (17) . The HCV RNA concentration was evaluated by the AMPLICOR HCV MONITOR assay according to the manufacturer's specifications. First, 100 l of serum, plasma, or control was coextracted by a guanidium-thiocyanate method with a quantitation standard (QS) with a known number of RNA copies. The QS is a synthetic RNA molecule with primer binding sites identical to those of wild-type HCV and with a unique probe binding site. The RNA and the QS were coprecipitated with isopropanol and were resuspended in a manganese-containing buffer. The extracted samples were added to a master mixture containing KY78 and KY80 primers, deoxynucleoside triphosphates, AmpErase, and rTth DNA polymerase. In the presence of manganese, rTth has both RT and DNA polymerase activities.
Samples were amplified with a 9600 thermocycler programmed in the following manner: holding for 2 min at 50ЊC, reverse transcription for 30 min at 60ЊC, denaturation for 1 min at 95ЊC, 2 cycles of 15 s at 95ЊC and 20 s at 60ЊC, 33 cycles of 15 s at 90ЊC and 20 s at 60ЊC, and a final 72ЊC extension for from 5 to 15 min. The samples were immediately denatured with 1.6% sodium hydroxide and were transferred to a probe-coated microwell plate containing hybridization solution. Rows A through E have wild-type probe KY150, while rows F through H are coated with a probe to the unique insert of the QS. Fivefold serial dilutions were made from rows A to E and rows F to H, so that rows A and F were undiluted while row E had a 1:625 dilution of wild-type target and row H was diluted 1:25. After the samples were incubated and washed, avidin-horseradish peroxidase was added. Following another incubation and washing, a substrate consisting of 0.1% 3,3Ј,5,5Ј-tetramethylbenzidine and 40 percent dimethylformamide was added. The microwell plate was read on a standard reader at a wavelength of 450 nm.
The quantities of viral HCV RNA were calculated by identifying the optical density values of the wild type in the wells in rows A through E and of the QS in the wells in rows F through H. For each group (rows A through E and rows F through H) the highest value between 0.2 and 2.0 was used in the calculations. Optical density values from which the background optical density had been subtracted were then multiplied by the respective dilution factor, and the resulting product for the wild-type wells was divided by the product for the QS. This number (total QS) was multiplied by 20,000 to convert to units of numbers of copies of HCV RNA per milliliter. Samples in rows F through H not having values of between 0.2 and 2.0 were invalid and the assay was repeated. For samples in rows F through H but not in rows A through E with values of between 0.2 and 2.0, HCV RNA was undetectable, falling below the level of sensitivity of the assay.
Statistical methods. The distribution of the HCV RNA concentrations was examined by using a scatter plot of the number of measurements (y axis) by the values (x axis). Since concentrations were not normally distributed, they were logarithmically transformed. A similar plot of log-transformed data demonstrated a normal distribution. Univariate analyses (Student's t test and analysis of variance) were performed with the log-transformed data. Because the data were highly correlated, that is, there were multiple measurements for each individual (autocorrelation), a generalized linear model (GLM) was used to estimate the independent level of association of each variate with the HCV RNA concentrations (22) . F tests were used to determine the statistical significance at the alpha level of 0.05. Adjusted geometric means are presented. Calculations were performed by using GLM in SAS.
RESULTS
Participants.
The median age of the participants was 38 years (range, 31 to 59 years) and nine subjects were male (Table 1 ). Exposure to HCV was presumed to be through injection drug use in five patients, blood transfusions in two patients, and unsterile percutaneous injections in one patient, while two subjects had no recognized risk factors. Among the six subjects who had liver biopsies, the histologic stage of disease included chronic persistent hepatitis (one patient), chronic active hepatitis (two patients), cirrhosis (two patients), and cirrhosis with hepatocellular cancer (one patient). All participants were anti-HCV positive, but HCV RNA could not be detected in one individual, whose data were therefore excluded from the final analyses.
HCV RNA concentrations. After excluding one subject in whom HCV RNA was undetectable, 40 HCV RNA determinations from a single blood draw were done for each of eight participants and 38 HCV RNA determinations were done for one participant (minus 2 determinations because of insufficient sample for laboratory B). The subjects' mean HCV RNA levels ranged from 132,000 to 724,000 copies per ml. To estimate the assay sensitivity, the HCV RNA concentration was assessed in 10-fold dilutions of an aliquot of blood from patient 8 at time zero (HCV RNA concentration of undiluted specimen, 938,000 copies per ml). HCV RNA was detected to a dilution of 1:10,000 (actual value, 358 copies per ml; expected value, 93.8 copies per ml) (Fig. 1) .
Interlaboratory variation. A total of 178 quantitative HCV RNA assessments were made in laboratory A and laboratory B. The median difference in measurements of HCV RNA concentrations between laboratories was 0.20 log (range, 0.01 to 0.88 log) (Fig. 2) . After using a GLM to account for autocorrelation and the effects of extrinsic factors, the adjusted mean HCV RNA concentration from laboratory A (385,000 copies per ml) was slightly lower than that from laboratory B (425,000 copies per ml) (standard deviation, 0.34 log; P ϭ 0.06) ( Table 2) .
Tube type. The three tube types containing blood from nine subjects were stored at the same temperature, centrifuged at five time points, and then assessed in two laboratories (although there was insufficient sample for one tube containing serum only and one tube containing ACD for laboratory B). The mean HCV RNA concentrations for tubes containing EDTA (426,000 copies per ml), serum (373,000 copies per ml), and ACD (393,000 copies per ml) were similar (P ϭ 0.44). In the multivariate GLM, the adjusted mean values were also similar (standard deviation, 0.16 log; P ϭ 0.22). Temperature. For each participant, the tubes containing EDTA were stored at room temperature and 4ЊC and were assessed at five time points in two laboratories. The adjusted and unadjusted mean HCV RNA concentrations were essentially identical after storage at the two temperatures (426,000 copies per ml) (P ϭ 0.99).
Time to centrifugation. At 0, 2, 6, 24, and 48 h after phlebotomy, one of each of three tube types and a tube containing EDTA at 4ЊC were centrifuged and aliquots were assessed in two laboratories. Over the 48-h time course, the mean HCV RNA concentration decreased from 698,000 copies per ml (0 h) to 520,000 copies per ml (48 h) (P ϭ 0.005). The adjusted mean HCV RNA concentrations also decreased with time to centrifugation (standard deviation, 0.36; P ϭ 0.005). Similar trends were seen for each subject (Fig. 3) . Statistically significant (P Ͻ 0.10) changes in HCV RNA concentration were not apparent when the samples were centrifuged within 6 h of collection. However, by 24 h the mean HCV RNA concentration declined by 63,000 copies per ml (P ϭ 0.04).
Precision. After accounting for intersubject variation and the laboratory, tube type, temperature, and time to centrifugation effects, the standard deviation of HCV RNA concentration measurements per subject was 0.22 log. Thus, for a given patient, changes of more than 0.44 log (two times the standard deviation) in HCV RNA concentration determined by a quantitative RT-PCR assay (AMPLICOR HCV MONI-TOR) were unlikely (P Ͻ 0.05) to be due to variations in test conditions.
DISCUSSION
The infectivities, severities, and therapeutic responses of infectious diseases have been assessed through quantitation of microbial markers. RNA concentrations in serum and plasma are increasingly being used to monitor chronic viral illnesses like HCV and human immunodeficiency virus infections (7, 13, 15) . However, for HCV only crude guidelines for the application of quantitative data are available. Pretreatment levels of HCV below 350,000 RNA equivalents per ml as measured by bDNA assay and the inability to detect RNA after treatment have been proposed as favorable therapeutic indicators (9, 13) . Similarly, the absence of HCV RNA has been correlated with decreased HCV transmission (21) . However, providers moni- a HCV RNA values were log transformed to approximate a normal distribution. Mean values were adjusted by using a GLM which accounts for repeated measurements from the same individual (autocorrelation), the between-subject variance, and the other factors listed in the trifugation, 95% of determinations were within 0.44 log. This suggests that repeated measurements of HCV RNA concentration that vary by less than 0.44 log should not be interpreted as indicating a significant biological change. Conversely, it is unlikely that fluctuations in HCV RNA concentrations of more than 1 log are due to the variance of the assay or to procurement or processing conditions. The comparability of quantitative HCV RNA test results from different laboratories using the same techniques is most important for clinical assessments. In the present study the mean HCV RNA concentrations between the two laboratories were slightly different (P ϭ 0.06). This information suggests that data from a single laboratory should ideally be used for comparisons of HCV RNA quantities. However, since 95% of test results were within 0.68 log and for some applications, like response to therapy, small variations in quantitative assessments are not critical, quantitative data from laboratories may be correlated with appropriate caution.
Because clinical and research sites and the reference laboratories that perform quantitative testing are often at different locations, the effect of the time to centrifugation on the HCV RNA concentration must also be known. In the present study, centrifugation of blood 24 h or more after collection resulted in a statistically significant reduction in the HCV RNA concentration as determined by a quantitative RT-PCR assay (AMPLICOR HCV MONITOR). The decrease in titer with time to centrifugation may be due to the destruction of HCV by RNases, whose effects are presumably reduced by clot removal. Alternatively, factors such as proteolytic enzymes that could affect the integrity of the virion could increase with time as cellular damage occurs. However, in the present study the HCV RNA concentration decreased only modestly when centrifugation was delayed 48 h, and for one individual, less than a 1-log reduction in the HCV RNA concentration was detected when centrifugation was delayed by 14 days (data not shown). Therefore, there appear to be individual differences in the presence of RNases and/or other factors that affect extracorporeal RNA survival.
Using the bDNA quantitative assay, Davis et al. (6) reported a 50% reduction in the HCV RNA concentration when centrifugation was delayed 6 h. Using a quantitative RT-PCR, we did not detect a significant difference at this time point. The extent to which this disparity relates to the assays is unknown. However, quantitative measurements from the two tests cannot be directly compared, since the assays use different amplification and detection methods. In a separate study, when seven specimens were tested by both assays, the results were highly correlated (r 2 ϭ 1.0) but data obtained by the bDNA quantitative assay were consistently 1 log higher than those obtained by the AMPLICOR HCV MONITOR RT-PCR (unpublished observations). Quantitative RT-PCR usually detects smaller quantities of HCV RNA than the bDNA assay (lower limit of 350,000 RNA equivalents per ml), while the bDNA assay generally has lower variance. Both factors could explain the difference in the findings of the two studies. A lower test variance results in a greater statistical power to detect decreases in the HCV RNA concentration. Alternatively, since values below the test cutoff were estimated by Davis et al. (6) to be 50% of the threshold, the decreased sensitivity of the bDNA assay could lead to an exaggerated estimate of RNA loss. Regardless, the results of the present study suggest that specimens centrifuged within 6 h of collection should provide results similar to those obtained by immediate processing when the specimens are tested by the AMPLICOR HCV MONI-TOR RT-PCR assay.
Conventional wisdom suggests that refrigeration retards RNA degeneration. However, in the present experiment refrigeration of EDTA-preserved blood prior to centrifugation had no effect on the HCV RNA concentration. Likewise, the AMPLICOR HCV MONITOR package insert recommends the collection of blood in tubes containing EDTA. However, in the present study no difference in HCV RNA concentration was found between tubes containing EDTA, ACD, or serum, a finding of significance to investigators considering quantitative assessments of HCV RNA in previously collected specimens or with ongoing protocols. These data indicate that the concentration of HCV RNA can be assessed by a commercially available RT-PCR assay. Blood specimens can be collected as plasma or serum and can remain at room temperature for up to 6 h until centrifugation. Serial HCV RNA titers should be performed in the same laboratory, and changes of less than 0.5 log may be due to chance. Further prospective study is needed to further elucidate the basis and clinical significance of fluctuations in HCV RNA levels in serial blood specimens.
